Showing results (301-310 of 322) with videos related to
Sort By:
Pageof 33
Biochemical Pharmacology|January 13, 2018
The structural determinants of the bitopic binding mode of a negative allosteric modulator of the dopamine D2 receptorChristopher J Draper-Joyce, Mayako Michino, Ravi Kumar Verma, et al.Science Signaling|May 25, 2017
Key determinants of selective binding and activation by the monocyte chemoattractant proteins at the chemokine receptor CCR2Zil E Huma, Julie Sanchez, Herman D Lim, et al.Journal of Medicinal Chemistry|May 20, 2021
Novel Dual-Target μ-Opioid Receptor and Dopamine D3 Receptor Ligands as Potential Nonaddictive Pharmacotherapeutics for Pain ManagementAlessandro Bonifazi, Francisco O Battiti, Julie Sanchez, et al.ACS Chemical Neuroscience|May 15, 2025
Identification of a Lipid-Exposed Extrahelical Binding Site for Positive Allosteric Modulators of the Dopamine D2 ReceptorHerman D Lim, Damian Bartuzi, Alastair C Keen, et al.Frontiers in Pharmacology|August 27, 2021
An Overview of Cell-Based Assay Platforms for the Solute Carrier Family of TransportersVojtech Dvorak, Tabea Wiedmer, Alvaro Ingles-Prieto, et al.Drug Discovery Today|April 17, 2017
Kinetics for Drug Discovery: an industry-driven effort to target drug residence timeDoris A Schuetz, Wilhelmus Egbertus Arnout de Witte, Yin Cheong Wong, et al.Journal of Medicinal Chemistry|August 1, 2025
Discovery, Characterization, and Optimization of a Novel Positive Allosteric Modulator-Antagonist of the D3 Dopamine ReceptorAmy E Moritz, Feijun Wang, Nora S Madaras, et al.Scientific Reports|January 21, 2018
The action of a negative allosteric modulator at the dopamine D2 receptor is dependent upon sodium ionsChristopher J Draper-Joyce, Ravi Kumar Verma, Mayako Michino, et al.Angewandte Chemie (International Ed. in English)|February 10, 2024
Discovery of the First-in-Class Inhibitors of Hypoxia Up-Regulated Protein 1 (HYOU1) Suppressing Pathogenic Fibroblast ActivationDimitra Papadopoulou, Vasiliki Mavrikaki, Filippos Charalampous, et al.Molecular Pharmacology|August 6, 2021
Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D2 Dopamine ReceptorR Benjamin Free, Caroline A Cuoco, Bing Xie, et al.Pageof 33